不同阳性阈值下粪便免疫化学检测用于结直肠癌筛查的表现
基于挪威结直肠癌筛查试验47,265名50-74岁首次参与者的数据,评估不同粪便免疫化学检测(FIT)阈值下结肠镜检查数、不良事件和病变检出情况。提高FIT阈值减少结肠镜检查需求,但大幅降低病变检出并改变结直肠癌分期分布,且结肠镜检查不良事件风险随阈值升高而增加。
要点
- FIT阈值从15 μg/g升至47 μg/g,结肠镜检查减少49.3%,结直肠癌检出降至75.9%。
- FIT阈值升至150 μg/g,结肠镜检查减少22.6%,结直肠癌检出降至56.2%。
- 结肠镜后出血率在15 μg/g为0.8%,150 μg/g为1.7%。
核心结论
- 提高FIT阈值减少结肠镜检查需求,但大幅降低病变检出并不利地改变结直肠癌分期分布。
- 结肠镜检查不良事件风险随FIT阈值升高而增加,需要各国-specific的不良事件信息。
研究设计与样本
- 基于挪威结直肠癌筛查试验,纳入47,265名50-74岁首次参与两年一度FIT筛查的个体。
- FIT > 15 μg Hb/g粪便者转诊结肠镜检查,估算其他欧洲国家当前或近期使用的20至150 μg/g阈值下预期结肠镜检查数、不良事件和病变检出。
主要发现
- 15 μg/g阈值下,3705名参与者接受结肠镜检查,其中203例结直肠癌、1119例进展期腺瘤和256例进展期锯齿状病变。
- 47 μg/g阈值下,1826名(49.3%)接受结肠镜检查,154例(75.9%)诊断为结直肠癌、702例(62.7%)进展期腺瘤和128例(50.0%)进展期锯齿状病变(与15 μg/g阈值相比)。
- 150 μg/g阈值下,838名(22.6%)接受结肠镜检查,114例(56.2%)结直肠癌、345例(30.8%)进展期腺瘤和54例(21.1%)进展期锯齿状病变。
- I期结直肠癌检出率在15 μg/g为0.22%,150 μg/g为0.11%。
- 结肠镜后出血率在15 μg/g为0.8%,150 μg/g为1.7%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The positivity thresholds of faecal immunochemical testing (FIT) in colorectal cancer (CRC) screening vary between countries. AIMS: To explore the trade-off between colonoscopies performed, adverse events and lesions detected at different FIT thresholds in a Norwegian CRC screening trial. METHODS: We included first participation in biennial FIT screening for 47,265 individuals aged 50-74 years. Individuals with FIT > 15 μg Hb/g faeces were referred for colonoscopy. We estimated the number of colonoscopies, adverse events, screen-detected CRCs, advanced adenomas and serrated lesions expected at FIT thresholds currently or recently used in other European countries ranging between 20 and 150 μg/g. RESULTS: At the 15 μg/g threshold (Norway), 3705 participants underwent colonoscopy, of whom 203 had CRC, 1119 advanced adenomas and 256 advanced serrated lesions. Using a 47 μg/g threshold, 1826 (49.3%) individuals would have undergone colonoscopy, and 154 (75.9%) would have been diagnosed with CRC, 702 (62.7%) with advanced adenoma and 128 (50.0%) with advanced serrated lesion compared to the 15 μg/g threshold. At 150 μg/g, the corresponding figures would have been 838 (22.6%) undergoing colonoscopy, 114 (56.2%) with CRC, 345 (30.8%) advanced adenoma and 54 (21.1%) advanced serrated lesions. The detection rate of stage I CRC was 0.22% at 15 μg/g and 0.11% at 150 μg/g. Post-colonoscopy bleeding rates were 0.8% and 1.7%, respectively. CONCLUSIONS: Increasing the FIT threshold reduces colonoscopy demand, but substantially decreases lesion detection and unfavourably changes CRC stage distribution. The risk of adverse events at colonoscopy increased with FIT threshold, requiring country-specific information on adverse events. TRIAL REGISTRATION: Clinicaltrials.gov identifier: NCT01538550.
引用
- Randel KR, Botteri E, de Lange T, et al. Performance of Faecal Immunochemical Testing for Colorectal Cancer Screening at Varying Positivity Thresholds. Aliment Pharmacol Ther. 2024. PMID: 39373173. doi:10.1111/apt.18314
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。